So far, only PD‐L1 IHC has been approved as a diagnostic biomarker by the US Food and Drug Administration for patients with advanced NSCLC for PD‐L1 status and patient selection for PD‐1/PD‐L1‐directed therapy.15 Here, CD274 is linked to non-small cell lung carcinoma.